Terms ending in 2035
Every in-force patent on Adma Biomanufacturing, LLC's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,107,906 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 9,714,283 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 9,815,886 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 9,969,793 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 10,683,343 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 11,339,206 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 11,780,906 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 12,473,351 | Compositions and Methods for the Treatment of Immunodeficiency In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.